YAP1 and cancer: According to a previous study, NF2-deficient PRCC cancers that have lost the capacity of regulating the Hippo signaling pathway could be treated with dasatinib, which targets Yes in YAP-activated tumors and inhibits its expression (Sourbier et al. 2018).